KYVINZIO — 2120791
Application number
2120791
Registration number
TMA1186427
International Registration Number
1602891
Type(s)
Standard Characters
Category
Trademark
CIPO Status
REGISTERED
TM5 status
LIVE/REGISTRATION/Issued
and Active
The trademark application has been registered with the Office.
Filed
2021-04-29
International Registration
2021-04-29
Registered
2023-06-21
Registration Expiry Date
2031-04-29
Registered Owner
Glaxo Group Limited
GSK Medicines Research Centre
Gunnels Wood Road, Stevenage SG1 2NY
UNITED KINGDOM
Agent
BORDEN LADNER GERVAIS LLP
World Exchange Plaza
100 Queen Street, Suite 1300
Ottawa
ONTARIO K1P1J9
Documents
Index headings
- KYVINZIO
Goods (Nice class & Statement)
- 5
- (1) Pharmaceutical preparations for use as anti-infectives, none relating to oncology; pharmaceutical preparations for the treatment of viral conditions, namely human immunodeficiency virus (HIV), human papilloma virus (HPV), respiratory syncytial virus (RSV), hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, Epstein-Barr virus and cytomegalovirus, none relating to oncology; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms, none relating to oncology; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely immunosuppressants, none relating to oncology; pharmaceutical preparations for the treatment of immunologic diseases and disorders namely, autoimmune diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of atherosclerosis, none relating to oncology; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders namely disorders of the endocrine system, namely growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management, none relating to oncology; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders namely arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis, none relating to oncology; pharmaceutical preparations for the treatment of blood-related diseases and disorders namely thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood, none relating to oncology; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis, none relating to oncology; pharmaceutical preparations for use in ophthalmology, none relating to oncology; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and skin structure infections namely bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases, none relating to oncology; pharmaceutical preparations for the treatment of hormonal related diseases and disorders namely hypogonadism, testosterone disorders, androgen disorders and estrogen disorders, none relating to oncology; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders namely irritable bowel disorders and symptoms, digestive disorders and acid-related disorders, namely acidifiers to increase levels of gastric acid to decrease stomach pH for human purposes, none relating to oncology; pharmaceutical preparations for the treatment of sexual dysfunction namely erectile dysfunction, male and female sexual dysfunction disorders namely arousal disorder, pain disorder, desire disorder and orgasm disorder, none relating to oncology; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of gynaecological diseases and disorders namely amenorrhoea, dysmenorrheal and infertility, none relating to oncology; pharmaceutical hormonal preparations namely corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations, none relating to oncology; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders, none relating to oncology; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor symptoms, menopausal symptoms, endometriosis, uterine fibroids, Leiomyoma, endourological disorders and for the removal of renal calculi and the treatment of nephrolithiasis and urolithiasis, pre-eclampsia and pre-term labour, none relating to oncology; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease, none relating to oncology; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders namely polycystic ovary syndrome, none relating to oncology; pharmaceutical preparations for the treatment of hepatological related diseases namely hepatitis, non-nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibroids, and cirrhosis, none relating to oncology; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness), none relating to oncology; pharmaceutical preparations for the treatment of psychiatric diseases and disorders namely mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses, none relating to oncology; pharmaceutical preparations for the treatment of damaged skin and tissue namely bee stings, sunburn, rashes, sores, corns, calluses and acne, none relating to oncology; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries, none relating to oncology; pharmaceutical preparations for the treatment of malaria, none relating to oncology; pharmaceutical preparations for the treatment of tuberculosis, none relating to oncology; allergy medications, none relating to oncology; vaccines namely prophylactic and therapeutic vaccines for humans, none relating to oncology; pharmaceutical preparations for the treatment of neurological diseases and disorders namely Parkinsons disease, Alzheimers disease, Huntingtons disease, dementia, migraine, cerebral palsy, brain injury, spinal cord injury, seizure disorders, epilepsy, restless legs syndrome, pain, neuropathic pain, inflammatory-related pain, fibromyalgia, stroke, multiple sclerosis, insomnia, none relating to oncology; pharmaceutical preparations for the treatment of central nervous system diseases and disorders namely central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, depression and anxiety and their related disorders namely schizophrenia and psychoses, none relating to oncology; pharmaceutical preparations for the treatment of muscular dystrophy, none relating to oncology.
Claims
- Priority Filing Date: April 19, 2021, Country or Office: UNITED KINGDOM, Application No. UK00003628645 in association with the same kind of goods
Recordals (known also as Footnotes)
CHANGE IN TITLE / CHANGEMENT EN TITRE: TYPE OF CHANGE / GENRE DE CHANGEMENT: Name and Address / Nom et adresse DATE REGISTERED / DATE DE L'ENREGISTREMENT: 2023-07-26 DATE OF CHANGE / DATE DE CHANGEMENT: 2023-06-28 COMMENTS / COMMENTAIRES: From: Glaxo Group Limited To: Glaxo Group LimitedAction History
| Action | Action date | Due date | Comments |
|---|---|---|---|
| Filed | 2021-04-29 | Registration | |
| International Registration | 2021-04-29 | 2031-04-29 | |
| Created | 2021-07-14 | ||
| Formalized | 2021-07-14 | ||
| Designation Notification - Madrid Protocol | 2021-07-15 | 2023-01-15 | |
| Limitation | 2022-01-07 | DP:2022-02-11 | |
| Partial Ceasing of Effect Received - No Amendments Required | 2022-03-28 | DP:2022-11-18 Effective date: 2022-02-18 | |
| Notification of Possible Opposition Sent | 2022-05-16 | ||
| Search Recorded | 2022-11-21 | ||
| Examiner's First Report | 2022-11-21 | 2023-05-21 | |
| Total Provisional Refusal | 2022-11-21 | 2023-05-21 | |
| Agent Changed | 2023-01-10 | From/De: To/A: 4 | |
| Approved | 2023-03-02 | APPROVED BY PROGRAM EX200M1 | |
| Approval Notice Sent | 2023-03-02 | APPROVED BY PROGRAM EX200M1 | |
| Advertised | 2023-03-29 | Vol.70 Issue 3570 | |
| Opposition Start Date Notice Sent | 2023-03-29 | Requested on 2023/03/29 03:30:20 in program jr500m1 | |
| Registration Pending | 2023-06-21 | ||
| Registered | 2023-06-21 | ||
| Statement of Grant of Protection Sent (following a Provisional Refusal) | 2023-06-21 | ||
| Amendment to Registration | 2023-07-27 | DP:2023-07-26 Effective Date: 2023-06-28 |